Dovetail Genomics Announces New Capture Hi-C Targeted Enrichment Panels
Dovetail Genomics, a leader in genomic solutions, has launched its new capture Hi-C technology, which includes two targeted enrichment panels for human and mouse samples. These products enable analysis of chromatin topology surrounding 80,000 gene promoters, significantly reducing the sequencing burden by over 90%. The collaboration with Twist Bioscience enhances this offering with its proprietary enrichment technology, promising advancements in research addressing gene expression. CEO statements highlight the potential for new biomarkers and improved understanding of disease mechanisms.
- New capture Hi-C technology reduces sequencing costs by over 90%.
- Enables analysis of chromatin topology for 80,000 gene promoters.
- Partnership with Twist Bioscience enhances product capabilities.
- Potential to discover new biomarkers for human disease.
- None.
SCOTTS VALLEY, Calif., June 16, 2021 /PRNewswire/ -- Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced availability of its new line of capture Hi-C technology. The flagship products include two targeted enrichment panels, the Dovetail® Human Pan Promoter Enrichment Kit, and the Dovetail® Mouse Pan Promoter Enrichment Kit, enabling the interrogation of chromatin topology surrounding 80,000 coding and non-coding gene promoters for human and mouse samples respectively. Dovetail's solution incorporates Twist Bioscience's (Nasdaq: TWST) proprietary targeted enrichment technology and is matched with Dovetail's unique Micro-C and Omni-C® Assays, each of which utilize sequence-independent nucleases for superior coverage compared to restriction enzyme-based Hi-C methodologies.
Genome-wide Hi-C studies have been highly informative in defining the critical relationship between chromosome architecture and gene expression. However, the sequencing depth required can be a significant barrier to larger studies. Dovetail's new products reduce the sequencing burden by over
Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, stated, "We are thrilled to be collaborating with Dovetail Genomics to bring Twist's innovative targeted enrichment technology to new markets. With our incredibly flexible target enrichment design capabilities and precise DNA synthesis, Dovetail is developing new and innovative panels to advance the study of chromatin topology."
"The ability of regulatory elements to act across large genomic distances has long been known and, through chromatin conformation capture techniques, the looping events that bring promoters and their regulatory elements, such as transcriptional enhancers, into close proximity are just starting to be probed," said Todd Dickinson, CEO. "Our new panels now enable these experiments to be completed at a fraction of the cost of genome-wide Hi-C approaches. This opens up avenues for translational research that rely on larger sample cohorts. In working with Twist, we are confident that these new best-in-class tools will help to accelerate understanding of human disease mechanisms, aid in drug discovery programs and offer a novel and valuable class of biomarker benefiting human disease diagnosis and management."
About Dovetail Genomics
Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all. The company enables researchers and clinicians to solve complex problems involving de novo assembly, structural variation, chromatin epigenetics and topology analysis, cancer research, chromosome-scale phasing, and more by providing them a more comprehensive view of the genome. With 68 pending applications and 14 issued patents, its proprietary in vitro proximity ligation approach and assembly algorithms simplify genomic discovery by integrating the highest quality long-range genomic information with next-generation sequencing output. Dovetail is based in Scotts Valley, California. For more information on Dovetail, its technology, and service offerings, visit https://dovetailgenomics.com/targetedenrichment/. Follow Dovetail on Twitter @DTGenomics.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to the ability of Dovetail Genomics' new line of capture Hi-C technology to effectively address a broad variety of research questions, including larger translational studies, to open the potential for discovery of a new class of chromatin topology-based biomarker, to advance the study of chromatin topology, to accelerate understanding of human disease mechanisms, to aid in drug discovery programs and to offer a novel and valuable class of biomarker benefiting human disease diagnosis and management, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on May 7, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/dovetail-genomics-announces-new-capture-hi-c-targeted-enrichment-panels-301313465.html
SOURCE Dovetail Genomics LLC
FAQ
What is Dovetail Genomics' new capture Hi-C technology?
How does the new technology impact research costs?
What collaboration is mentioned in the press release?
What are the potential benefits of this technology?
What are the flagship products introduced?
